05.10.2016

Marcel Tanner appointed as “High Representative” of the European & Developing Countries Clinical Trials Partnership (EDCTP)

Marcel Tanner, leading global health specialist and former director of the Swiss Tropical and Public Health Institute (Swiss TPH), has been elected as “High Representative North” by the European & Developing Countries Clinical Trials Partnership (EDCTP) with a special focus on Europe. Leonardo Santos Simão, a former Minister of Health and Minister of Foreign Affairs and Cooperation of Mozambique, has been appointed as the EDCTP "High Representative South” with a special focus on Africa.

The High Representatives will act as goodwill ambassadors for EDCTP in order to increase the visibility of the programme and promote partnerships with other EDCTP stakeholders in the fight against poverty-related and neglected diseases in Africa, Europe and globally. “We are truly delighted to have two highly respected and experienced policy and research leaders with complementary track records and expertise join the EDCTP partnership as goodwill ambassadors”, writes Michael Makanga, EDCTP Executive Director, in the press release.

 

Important implications for Swiss science policy
Marcel Tanner’s election has important ramifications also for science policy in Switzerland. “Irrespective of current political issues and possible barriers, we shall continue bring together young and established scientists to move towards a more effective research and translational partnership for the benefit of the most neglected populations of our world”, says Marcel Tanner. Since the election pertaining to the mass immigration (“Masseneinwanderungsinitative”) in February 2014, Switzerland’s researchers have been partly excluded from important funding bodies such as the EU-Programme Horizon 2020.

 

About Marcel Tanner

 

Marcel Tanner is a globally renowned expert on public and global health. His broad experience spans communicable diseases control and health systems research to public and global health policy and strategy including healthcare and diplomacy at national and international levels. He has strong connections with both the private sector (including large pharmaceutical companies), and many government agencies for development cooperation. He was director of the Swiss TPH for the past 18 years and currently, he is President of the Swiss Academy of Sciences, Chair and member of the Board of Drugs for Neglected Diseases initiative (DNDi), and a member of the Board of FIND, INDEPTH and of planning and strategy committees of a number of funding agencies (WHO, Wellcome Trust, Bill & Melinda Gates Foundation). He is also a member of the Advisory Group for Horizon 2020’s Societal Challenge 1 (on Health, Demographic Change and Well-being) which contributes to setting programme priorities for 2018-2020.

 

Further information: Press Release EDCTP

 

 

 

 

back to list